ADTX
vs
S&P 500
ADTX
S&P 500
Over the past 12 months, ADTX has underperformed S&P 500, delivering a return of -100% compared to the S&P 500's +16% growth.
Stocks Performance
ADTX vs S&P 500
Performance Gap
ADTX vs S&P 500
Performance By Year
ADTX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Aditxt Inc
Glance View
Aditxt, Inc. engages in the development of biotechnologies specifically focused on improving the health of the immune system through immune reprogramming and monitoring. The company is headquartered in Richmond, Virginia and currently employs 58 full-time employees. The company went IPO on 2020-06-19. The firm is developing technologies focused on improving the health of the immune system through immune mapping and reprogramming. The Company’s immune mapping technologies are designed to provide a personalized comprehensive profile of the immune system. The Company’s Apoptotic DNA Immunotherapy (ADi) technology has two categories, the AditxtReprogramming therapeutic program, which includes ADi and the AditxtScore diagnostic technology. AditxtScore is designed to allow individuals to understand, manage and monitor their immune profiles in order to be informed about attacks on or by their immune system. AditxtScore also assists the medical community in anticipating immune responses and reactions to viruses, bacteria, allergens and transplanted organs. ADi is a nucleic acid-based technology that suppresses only those immune cells involved in the rejection of tissue and transplanted organ.
